Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"GentiBio","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","amount":"$157.0 million","upfrontCash":"Undisclosed","newsHeadline":"GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"GentiBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"Undisclosed","newsHeadline":"GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by GentiBio

    Menu

    GentiBio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              GentiBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases

              Details:

              GentiBio will apply its engineered regulatory T cell platform in a deal with BMS to develop new engineered Treg therapies to treat inflammatory bowel diseases.

              Lead Product(s): Egineered Treg Cell Therapy

              Therapeutic Area: Gastroenterology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Bristol Myers Squibb

              Deal Size: $1,900.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration August 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GentiBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics

              Details:

              Funding will advance novel pipeline of best-in-class engineered regulatory T cell therapies to durably restore immune tolerance and treat autoimmune, alloimmune, autoinflammatory, and allergic diseases.

              Lead Product(s): Engineered Regulatory T Cell Therapy

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Matrix Capital Management

              Deal Size: $157.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing August 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY